36825-36-2Relevant articles and documents
-
Baker et al.
, p. 704 (1947)
-
Synthetic method of 4-amino-6-nitro-3-bromoquinoline
-
Paragraph 0039-0041, (2017/02/28)
The invention relates to 4-amino-6-nitro-3-bromoquinoline that is a precursor for preparing nociceptin antagonists. The invention discloses a synthetic method of 4-amino-6-nitro-3-bromoquinoline. The synthetic method comprises the following steps: carrying out iron powder reduction reaction on 4-nitroquinoline-N-oxide, as a raw material, in the presence of acetic acid, so as to generate 4-aminoquinoline; carrying out bromination reaction, so as to generate 4-amino-3-bromoquinoline; finally carrying out nitration reaction, so as to generate 4-amino-6-nitro-3-bromoquinoline. The compound structure of 4-amino-6-nitro-3-bromoquinoline is represented by 1H-NMR, 13C-NMR and IR. The adopted raw materials and reagents are cheap and easily available, the synthetic method is simple and feasible, and reaction conditions are mild; according to the synthetic method, a simple and convenient synthetic way is developed for the synthesis of 4-amino-6-nitro-3-bromoquinoline compounds.
4-Aminoquinolines: Novel nociceptin antagonists with analgesic activity
Shinkai,Ito,Iida,Kitao,Yamada,Uchida
, p. 4667 - 4677 (2007/10/03)
Small-molecule nociceptin antagonists were synthesized to examine their therapeutic potential. After a 4-aminoquinoline derivative was found to bind with the human ORL1 receptor, a series of 4-aminoquinolines and related compounds were synthesized and their binding was evaluated. Elucidation of structure - Activity relationships eventually led to the optimum compounds. One of these compounds, N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide hydrochloride (11) not only antagonized nociceptin-induced allodynia in mice but also showed analgesic effect in a hot plate test using mice and in a formalin test using rats. Its analgesic effect was not antagonized by the opioid antagonist naloxone. These results indicate that this nociceptin antagonist has the potential to become a novel type of analgesic that differs from μ-opioid agonists.